Insider filing · SMMT

Mahkam Zanganeh bought $50.0M of Summit Therapeutics (SMMT)

Executed Jun 12, disclosed Jun 12, the same day.

Over the 21 trading sessions from the disclosed entry session (Jun 12), the stock returned +19.0% (delay-adjusted); from the execution session (Jun 12), +19.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

MZ Mahkam Zanganeh Co-Chief Executive Officer profile →

Mahkam Zanganeh (Co-Chief Executive Officer) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 3 priced purchase filings, the average 21-session return was +3.3% from execution and +4.0% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12.

SMMT Summit Therapeutics Inc. SMMT · Healthcare · 10 filings in 24 months ticker →

Healthcare · Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, care…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→